Merck (MRK) Stock Climbs After Q3 Results Revive Profit But Margins Lag

Merck stock climbed about 2.2% on Friday to roughly US$149.54 as investors reacted to fresh Q3 2026 earnings. At first glance the move looks routine. A closer look at the print is anything but.

The headline this quarter is earnings power snapping back. Merck reported basic earnings per share of about US$2.04 and net income of roughly US$5.1b for the period, a sharp contrast to the losses booked earlier in 2026. Short term traders are cheering the bounce. Long term holders are weighing that profit recovery against earlier margin compression and the elevated debt load that still hangs over the balance sheet.

If you like the earnings rebound at Merck but are uneasy about earlier margin pressure and the heavier balance sheet, consider reviewing list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): US$18,085 million vs. US$17,276 million (up about 5%)
• Net Income, Excl. Extra Items (Q3 2026 vs Q3 2025): US$5,065 million vs. US$5,785 million (down about 12%)
• Basic EPS (Q3 2026 vs Q3 2025): US$2.04 vs. US$2.32 (down about 12%)
• Trailing 12-Month Revenue (Q3 2026 TTM vs Q3 2025 TTM): US$67,378 million vs. US$64,235 million (up about 5%)

Earnings show what Merck booked this quarter, but the cash that actually came through the business is what valuation focused investors often study most closely.

When you focus on Merck's cash flows instead of the income statement noise, the stock could be a dramatic 37% undervalued.

Merck Earnings Test Pipeline Led Margin Story

The bullish story argues that Merck can use breadth and new volume to keep profitability intact as Keytruda eventually fades.

"Merck’s use of AI in molecular design and optimization, which management links to higher probability of technical and regulatory success and to tangible R&D cost and speed benefits, introduces the potential for a structurally more efficient discovery engine that supports a larger late stage portfolio without a proportional rise in R&D spend and therefore supports margin and earnings expansion."

Q3 results partially back that idea. Oncology assets like sac TMT, INTerpath 001 and subcutaneous Keytruda QLEX are clearing late stage hurdles, and new products such as WINREVAIR and LIPFENDRA are already contributing. At the same time, operating expenses rose 12%, so margin expansion from efficiency is not visible yet.

The price and this Narrative do not agree. → Uncover what this Narrative says Merck is actually worth.

Merck Bear Case: Execution Risk Still Has Teeth

Bearish investors worry Merck may stay too reliant on a few oncology blockbusters just as patent pressure builds and diversification efforts hit setbacks.

"Although Merck highlights a broad ADC pipeline anchored by sac TMT with many Phase III studies, the voluntary withdrawal of the ifinatamab deruxtecan application after safety and data adequacy concerns raises the risk that other next generation oncology assets could face regulatory pushback or safety related label constraints, which would weigh on future oncology revenue and delay the earnings contribution management is targeting from this modality."

Q3 progress from sac TMT helps, yet the I DXd withdrawal and remigromig safety overhang mean part of the antibody drug conjugate and ophthalmology story is already slipping behind the clean, high confidence diversification arc that bearish analysts question. Operating expenses rising 12% while margin expansion remains elusive adds weight to concerns about a productivity gap between R&D spend and late stage output.

Hunt For Mispriced Earnings Power

Merck shows how quickly sentiment can change when earnings surprise the market. The real opportunity is finding stocks that could be undervalued before the market corrects them.

• Company 1 - 41% below our estimate - uses recyclable access mats to support long term utility and infrastructure rental activity.
• Company 2 - 42% below our estimate - sells modular data center building blocks for buyers scaling demanding AI and high performance computing workloads.
• Company 3 - 46% below our estimate - enables large online platforms to route complex local payments as they expand into new channels.

Those are three of them. See every one of the 30 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com